Filing Details
- Accession Number:
- 0001415889-24-025601
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-10-24 16:15:07
- Reporting Period:
- 2024-09-13
- Accepted Time:
- 2024-10-24 16:15:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1817713 | Janux Therapeutics Inc. | JANX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1376355 | Jay Lichter | 11099 N Torrey Pines Road, Suite 290 La Jolla CA 92037 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-09-13 | 1,868 | $17.00 | 8,868 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-09-13 | 778 | $10.73 | 9,646 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-09-13 | 778 | $13.22 | 10,424 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-09-13 | 391 | $39.80 | 10,815 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-09-13 | 3,815 | $46.68 | 7,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-09-13 | 1,868 | $0.00 | 1,868 | $17.00 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-09-13 | 778 | $0.00 | 778 | $10.73 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-09-13 | 778 | $0.00 | 778 | $13.22 |
| Common Stock | Stock Option (right to buy) | Disposition | 2024-09-13 | 391 | $0.00 | 391 | $39.80 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 27,138 | 2027-07-19 | No | 4 | M | Direct | |
| 11,308 | 2027-07-19 | No | 4 | M | Direct | |
| 11,308 | 2027-07-19 | No | 4 | M | Direct | |
| 7,682 | 2027-07-19 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 2,959,175 | Indirect | By Avalon Ventures XI, L.P. |
| Common Stock | 573,227 | Indirect | By Avalon BioVentures I, LP |
| Common Stock | 3,021,414 | Indirect | By Avalon BioVentures SPV I, L.P. |
Footnotes
- The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- Immediately exercisable.
Billionaire Hedge Funds
